Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in...
Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies
Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple...
Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases
Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of...
Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version...
Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design
Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company...
Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy – Once-Yearly ASO with Novel Chemical Structure
Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food...
Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer – CLDN18.2-Targeting ADC Files NDA with NMPA
Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase...
Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD
Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks...
Jiangsu Vcare PharmaTech Secures NMPA Approval for Eratrectinib – Next-Generation TRK Inhibitor with Enhanced Brain Penetration and Circular Molecular Structure
Jiangsu Vcare PharmaTech Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
GE HealthCare Secures FDA 510(k) Clearance for MIM Contour ProtégéAI+ 2.0 – AI Auto-Contouring Platform with Predetermined Change Control Plan
GE HealthCare (NASDAQ: GEHC) announced it has received 510(k) clearance from the United States Food...
Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...
Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE
Johnson & Johnson (J&J, NYSE: JNJ) announced positive results from the Phase II JASMINE study...
Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery
H. Lundbeck A/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle,...
Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration
Medtronic plc (NYSE: MDT) announced on June 3, 2026, strategic investments in two privately held...
Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has significantly expanded its collaboration with fellow US biotechnology company...
Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases
Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research...
Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument
Medtronic plc (NYSE: MDT) announced on June 3, 2026, the submission of 510(k) premarket notifications...
Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market
Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced...
Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical...